Nektar Therapeutics (NKTR) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1158016,
    "name": "Nektar Therapeutics",
    "stock_name": "Nektar Therapeutics",
    "full_name": "Nektar Therapeutics",
    "name_url": "stocks-analysis/nektar-therapeutics",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "57.69",
    "chg": 2.84,
    "chgp": "5.18%",
    "dir": 1,
    "prev_price": "54.85",
    "mcapval": "867.58",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US6402681083",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "952.19 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/nektar-therapeutics-1158016-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Nektar Therapeutics Stock Hits Day Low Amid Price Pressure at $55.51",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nektar-therapeutics-stock-hits-day-low-amid-price-pressure-at-5551-3574354",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/NektarTherapeut_priceRelatedfactors_3574354.png",
        "date": "2025-09-26 14:24:15",
        "description": "Nektar Therapeutics faced a notable decline in its stock price today, reaching an intraday low. While the company has shown impressive growth over the past month, its long-term fundamentals remain weak, with declining net sales and operating profit, alongside concerns about its ability to service debt."
      },
      {
        "title": "Nektar Therapeutics Hits New 52-Week High of $61.15, Up 233.78%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nektar-therapeutics-hits-new-52-week-high-of-6115-up-23378-3571285",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/NektarTherapeut_priceRelatedfactors_3571285.png",
        "date": "2025-09-25 16:39:34",
        "description": "Nektar Therapeutics achieved a new 52-week high of USD 61.15 on September 24, 2025, reflecting a significant increase in stock performance over the past year. With a market capitalization of USD 868 million, the company operates at a loss but shows strong return on equity and notable financial leverage."
      },
      {
        "title": "Nektar Therapeutics Hits New 52-Week High of $61.06, Up 229.74%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nektar-therapeutics-hits-new-52-week-high-of-6106-up-22974-3565215",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/NektarTherapeut_priceRelatedfactors_3565215.png",
        "date": "2025-09-24 13:14:28",
        "description": "Nektar Therapeutics has achieved a new 52-week high, reflecting a substantial increase over the past year, significantly outpacing broader market growth. With a market capitalization of USD 868 million, the company exhibits strong profitability metrics but remains loss-making, indicating a volatile yet promising position in the biotechnology sector."
      },
      {
        "title": "Nektar Therapeutics Hits New 52-Week High of $59.58, Soars 205%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nektar-therapeutics-hits-new-52-week-high-of-5958-soars-205-3552466",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/NektarTherapeut_priceRelatedfactors_3552466.png",
        "date": "2025-09-22 18:05:27",
        "description": "Nektar Therapeutics achieved a new 52-week high of USD 59.58 on September 19, 2025, reflecting a 205.06% increase over the past year. The company, with a market cap of USD 868 million, shows strong financial metrics but remains loss-making, highlighting its unique position in the biotechnology sector."
      },
      {
        "title": "Is Nektar Therapeutics technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-nektar-therapeutics-technically-bullish-or-bearish-3545436",
        "imagepath": "",
        "date": "2025-09-20 19:11:46",
        "description": "As of 5 September 2025, the technical trend for Nektar Therapeutics has changed from mildly bullish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. Bollinger Bands are bullish on both weekly and monthly time frames. Daily moving averages indicate a bullish stance. However, the RSI shows bearish readings for both weekly and monthly periods. The KST is bullish on both time frames, and the Dow Theory indicates a mildly bullish stance on both weekly and monthly charts. The OBV shows no trend weekly but is bullish monthly.\n\nNektar Therapeutics has significantly outperformed the S&P 500 over the past week (24.49% vs. 1.05%) and month (114.22% vs. 2.33%), but has underperformed over longer periods, including the last three years (12.89% vs. 70.41%) and five years (-80.58% vs. 96.61%). Overall, the current technical stance is bullish, driven primarily by the strong performance in m..."
      },
      {
        "title": "Is Nektar Therapeutics overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-nektar-therapeutics-overvalued-or-undervalued-3542142",
        "imagepath": "",
        "date": "2025-09-20 17:45:51",
        "description": "As of 8 August 2019, the valuation grade for Nektar Therapeutics has moved from fair to risky, indicating a shift towards a more negative outlook. The company appears to be overvalued given its current financial metrics, particularly with a Price to Book Value of 9.02 and an EV to Sales ratio of 0.15, which suggests that the market is pricing in significant future growth despite the company's ongoing losses. Additionally, the negative ROE of -860.22% further underscores the challenges the company faces in generating returns for shareholders.\n\nIn comparison with peers, Nektar Therapeutics has a P/E ratio of -7.21, which is significantly lower than typical industry valuations, indicating that it is not only struggling relative to its competitors but also facing severe operational difficulties. The stock has shown impressive short-term performance, with a 1-month return of 114.22% compared to the S&P 500's 2.3..."
      },
      {
        "title": "Nektar Therapeutics Hits Day High with 15.06% Surge in Stock Price",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nektar-therapeutics-hits-day-high-with-1506-surge-in-stock-price-3537250",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/NektarTherapeut_priceRelatedfactors_3537250.png",
        "date": "2025-09-19 13:34:58",
        "description": "Nektar Therapeutics has seen significant stock activity, with a notable rise today and impressive gains over the past week and month. Despite these short-term successes, the company faces challenges such as declining net sales, operating losses, and a negative EBITDA, raising concerns about its long-term fundamentals."
      },
      {
        "title": "Nektar Therapeutics Hits New 52-Week High of $58.81, Up 225%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nektar-therapeutics-hits-new-52-week-high-of-5881-up-225-3536929",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/NektarTherapeut_priceRelatedfactors_3536929.png",
        "date": "2025-09-19 12:53:24",
        "description": "Nektar Therapeutics has achieved a new 52-week high of USD 58.81, reflecting a significant growth trajectory with a 225.09% increase in stock price over the past year. Despite its current loss-making status, the company boasts a market capitalization of USD 868 million and an impressive return on equity of 496.67%."
      },
      {
        "title": "Nektar Therapeutics Hits New 52-Week High of $52.75, Up 182.54%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/nektar-therapeutics-hits-new-52-week-high-of-5275-up-18254-3531360",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/NektarTherapeut_priceRelatedfactors_3531360.png",
        "date": "2025-09-18 13:11:38",
        "description": "Nektar Therapeutics has achieved a new 52-week high, reflecting significant growth in the Pharmaceuticals & Biotechnology sector. With a market capitalization of USD 868 million, the company has shown impressive performance over the past year, despite operating at a loss and having unique financial metrics."
      }
    ],
    "total": 14,
    "sid": "1158016",
    "stock_news_url": "https://www.marketsmojo.com/news/nektar-therapeutics-1158016"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Nektar Therapeutics Stock Hits Day Low Amid Price Pressure at $55.51

2025-09-26 14:24:15

Nektar Therapeutics faced a notable decline in its stock price today, reaching an intraday low. While the company has shown impressive growth over the past month, its long-term fundamentals remain weak, with declining net sales and operating profit, alongside concerns about its ability to service debt.

Nektar Therapeutics Hits New 52-Week High of $61.15, Up 233.78%

2025-09-25 16:39:34

Nektar Therapeutics achieved a new 52-week high of USD 61.15 on September 24, 2025, reflecting a significant increase in stock performance over the past year. With a market capitalization of USD 868 million, the company operates at a loss but shows strong return on equity and notable financial leverage.

Nektar Therapeutics Hits New 52-Week High of $61.06, Up 229.74%

2025-09-24 13:14:28

Nektar Therapeutics has achieved a new 52-week high, reflecting a substantial increase over the past year, significantly outpacing broader market growth. With a market capitalization of USD 868 million, the company exhibits strong profitability metrics but remains loss-making, indicating a volatile yet promising position in the biotechnology sector.

Nektar Therapeutics Hits New 52-Week High of $59.58, Soars 205%

2025-09-22 18:05:27

Nektar Therapeutics achieved a new 52-week high of USD 59.58 on September 19, 2025, reflecting a 205.06% increase over the past year. The company, with a market cap of USD 868 million, shows strong financial metrics but remains loss-making, highlighting its unique position in the biotechnology sector.

Is Nektar Therapeutics technically bullish or bearish?

2025-09-20 19:11:46

As of 5 September 2025, the technical trend for Nektar Therapeutics has changed from mildly bullish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. Bollinger Bands are bullish on both weekly and monthly time frames. Daily moving averages indicate a bullish stance. However, the RSI shows bearish readings for both weekly and monthly periods. The KST is bullish on both time frames, and the Dow Theory indicates a mildly bullish stance on both weekly and monthly charts. The OBV shows no trend weekly but is bullish monthly. Nektar Therapeutics has significantly outperformed the S&P 500 over the past week (24.49% vs. 1.05%) and month (114.22% vs. 2.33%), but has underperformed over longer periods, including the last three years (12.89% vs. 70.41%) and five years (-80.58% vs. 96.61%). Overall, the current technical stance is bullish, driven primarily by the strong performance in m...

Is Nektar Therapeutics overvalued or undervalued?

2025-09-20 17:45:51

As of 8 August 2019, the valuation grade for Nektar Therapeutics has moved from fair to risky, indicating a shift towards a more negative outlook. The company appears to be overvalued given its current financial metrics, particularly with a Price to Book Value of 9.02 and an EV to Sales ratio of 0.15, which suggests that the market is pricing in significant future growth despite the company's ongoing losses. Additionally, the negative ROE of -860.22% further underscores the challenges the company faces in generating returns for shareholders. In comparison with peers, Nektar Therapeutics has a P/E ratio of -7.21, which is significantly lower than typical industry valuations, indicating that it is not only struggling relative to its competitors but also facing severe operational difficulties. The stock has shown impressive short-term performance, with a 1-month return of 114.22% compared to the S&P 500's 2.3...

Nektar Therapeutics Hits Day High with 15.06% Surge in Stock Price

2025-09-19 13:34:58

Nektar Therapeutics has seen significant stock activity, with a notable rise today and impressive gains over the past week and month. Despite these short-term successes, the company faces challenges such as declining net sales, operating losses, and a negative EBITDA, raising concerns about its long-term fundamentals.

Nektar Therapeutics Hits New 52-Week High of $58.81, Up 225%

2025-09-19 12:53:24

Nektar Therapeutics has achieved a new 52-week high of USD 58.81, reflecting a significant growth trajectory with a 225.09% increase in stock price over the past year. Despite its current loss-making status, the company boasts a market capitalization of USD 868 million and an impressive return on equity of 496.67%.

Nektar Therapeutics Hits New 52-Week High of $52.75, Up 182.54%

2025-09-18 13:11:38

Nektar Therapeutics has achieved a new 52-week high, reflecting significant growth in the Pharmaceuticals & Biotechnology sector. With a market capitalization of USD 868 million, the company has shown impressive performance over the past year, despite operating at a loss and having unique financial metrics.

View All News